Rheumatologists should develop a plan to keep in step with federal regulations
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Medical Device Safety Concerns Rheumatologists
Are recent controversies over metal-on-metal hip replacements and an IOM report cause for worry?
Take Our Regulators—Please!
May 2009 bring us a return to constructive, thoughtful oversight in all fields
Medicine’s for the Birds
In the healthcare game plan, how will physicians get the ball?
Your Representatives on Capitol Hill
Government Affairs Committee advocates on behalf of the ACR and all rheumatologists